50976-96-0

Basic information

• Product Name: 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,2-diol
• Synonyms: 4H-dibenzo[de,g]quinoline-1,2-diol, 5,6,6a,7-tetrahydro-6-methyl-; 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,2-diol
• CAS NO: 50976-96-0
• Molecular Formula: C₁₇H₁₇NO₂
• Molecular Weight: 267.3224
• Mol File: 50976-96-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 472.1°C at 760 mmHg
• Flash Point: 267.6°C
• Density: 1.299g/cm³
• Vapor Pressure: 1.55E-09mmHg at 25°C
• Refractive Index: 1.681
• CAS DataBase Reference: 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,2-diol(50976-96-0)
• EPA Substance Registry System: 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,2-diol(50976-96-0)

Safety Data

• Hazardous Substances Data: 50976-96-0(Hazardous Substances Data)

Upstream product

• 5868-18-8 nuciferine 
• 37082-15-8 (6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-ol 
• 475-83-2 R-(-)-nuciferine 
• 839673-82-4 1-(2'-bromobenzyl)-N-tert-butyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 78946-19-7 1-(2'-bromobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 80041-81-2 1-(2-bromobenzyl)-3,4-dihydro-6,7-dimethoxyisoquinoline 
• 109558-14-7 β-(3,4-dimethoxyphenyl)ethyl-(2'-bromophenyl)acetamide 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 108-73-6 3,5-dihydroxyphenol 
• 17669-16-8 (-)-roemerine hydrochloride 

Relevant articles and documents

1-(2′-Bromobenzyl)-6,7-dihydroxy- N-methyl-tetrahydroisoquinoline and 1,2-Demethyl-nuciferine as Agonists in Human D2 Dopamine Receptors

Certain D2-like dopamine receptor (DR) agonists are useful therapeutically as antiparkinsonian drugs, whereas D2-like DR antagonists or partial agonists are proven effective as antipsychotics. Two isoquinoline derivatives, 1-(2′-brom

3,4-Dihydroxy- and 3,4-methylenedioxy- phenanthrene-type alkaloids with high selectivity for D2 dopamine receptor

Dopamine-mediated neurotransmission plays an important role in relevant psychiatric and neurological disorders. Nowadays, there is an enormous interest in the development of new drugs acting at the dopamine receptors (DR) as potential new targets for the